Search Results

(±)-10-Hydroxycamptothecin 50 mg  | 99.58%

TargetMol

(±)-10-Hydroxycamptothecin is an alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.

More Information Supplier Page

Erdosteine 50 mg  | Purity Not Available

TargetMol

Erdosteine is a homocysteine-derived thiol derivative with mucolytic and free radical scavenging properties. Erdosteine and its metabolites modulate mucus production and viscosity, by which facilitating mucociliary transport and improving expectoration. This agent also suppresses the chemical-induced cough reflex as well as protects lung tissues from damages caused by cigarette smoking mediated through free radicals scavenging.

More Information Supplier Page

Hydrocortisone acetate 100 mg  | 99.58%

TargetMol

Hydrocortisone acetate is the synthetic acetate salt form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.

More Information Supplier Page

Hydrocortisone acetate 200 mg  | 99.58%

TargetMol

Hydrocortisone acetate is the synthetic acetate salt form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.

More Information Supplier Page

Dirithromycin 200 mg  | 99.59%

TargetMol

Dirithromycin is a macrolide glycopeptide antibiotic. It is used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.

More Information Supplier Page

Trimetazidine dihydrochloride 100 mg  | Purity Not Available

TargetMol

Trimetazidine dihydrochloride can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

More Information Supplier Page

Roflumilast 25 mg  | 99.64%

TargetMol

Roflumilast is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3′, 5′-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

More Information Supplier Page